BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24424563)

  • 21. Differentiating Mass-Forming Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma on the Basis of Contrast-Enhanced MRI and DWI Findings.
    Choi SY; Kim SH; Kang TW; Song KD; Park HJ; Choi YH
    AJR Am J Roentgenol; 2016 Feb; 206(2):291-300. PubMed ID: 26797355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis of autoimmune pancreatitis using endoscopic ultrasonography.
    Hoki N; Mizuno N; Sawaki A; Tajika M; Takayama R; Shimizu Y; Bhatia V; Yamao K
    J Gastroenterol; 2009; 44(2):154-9. PubMed ID: 19214678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI features for differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Ha J; Choi SH; Kim KW; Kim JH; Kim HJ
    Dig Liver Dis; 2022 Jul; 54(7):849-856. PubMed ID: 34903501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmune pancreatitis: assessment of the enhanced duct sign on multiphase contrast-enhanced computed tomography.
    Kawai Y; Suzuki K; Itoh S; Takada A; Mori Y; Naganawa S
    Eur J Radiol; 2012 Nov; 81(11):3055-60. PubMed ID: 22613506
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Zhang J; Jia G; Zuo C; Jia N; Wang H
    BMC Cancer; 2017 Oct; 17(1):695. PubMed ID: 29061130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of pancreatography for diagnosing autoimmune pancreatitis.
    Takuma K; Kamisawa T; Tabata T; Inaba Y; Egawa N; Igarashi Y
    World J Gastroenterol; 2011 May; 17(18):2332-7. PubMed ID: 21633599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic duct "Icicle sign" on MRI for distinguishing autoimmune pancreatitis from pancreatic ductal adenocarcinoma in the proximal pancreas.
    Kim HJ; Kim YK; Jeong WK; Lee WJ; Choi D
    Eur Radiol; 2015 Jun; 25(6):1551-60. PubMed ID: 25501271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging diagnosis of autoimmune pancreatitis using endoscopic ultrasonography.
    Ishikawa T; Kawashima H; Ohno E; Mizutani Y; Fujishiro M
    J Med Ultrason (2001); 2021 Oct; 48(4):543-553. PubMed ID: 34669071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and imaging features of autoimmune pancreatitis with focal pancreatic swelling or mass formation: comparison with so-called tumor-forming pancreatitis and pancreatic carcinoma.
    Wakabayashi T; Kawaura Y; Satomura Y; Watanabe H; Motoo Y; Okai T; Sawabu N
    Am J Gastroenterol; 2003 Dec; 98(12):2679-87. PubMed ID: 14687817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer.
    Cho MK; Moon SH; Song TJ; Kim RE; Oh DW; Park DH; Lee SS; Seo DW; Lee SK; Kim MH
    Gut Liver; 2018 Sep; 12(5):591-596. PubMed ID: 29699060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoimmune pancreatitis: imaging features.
    Sahani DV; Kalva SP; Farrell J; Maher MM; Saini S; Mueller PR; Lauwers GY; Fernandez CD; Warshaw AL; Simeone JF
    Radiology; 2004 Nov; 233(2):345-52. PubMed ID: 15459324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase.
    Kwon JH; Kim JH; Kim SY; Byun JH; Kim HJ; Lee MG; Lee SS
    Eur Radiol; 2019 Nov; 29(11):5763-5771. PubMed ID: 31028441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Imaging features of autoimmune pancreatitis].
    Cong GN; Qin MW; You H; Liu W; Xu K
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):479-84. PubMed ID: 18795625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study.
    Moon SH; Kim MH; Park DH; Hwang CY; Park SJ; Lee SS; Seo DW; Lee SK
    Gut; 2008 Dec; 57(12):1704-12. PubMed ID: 18583399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of CT findings of biliary tract changes with autoimmune pancreatitis and extrahepatic bile duct cholangiocarcinoma.
    Maeda E; Akahane M; Yoshioka N; Takao H; Matsuda I; Kamiya K; Hirano K; Tada M; Ohtsu H; Fukushima N; Ohtomo K
    Jpn J Radiol; 2012 Apr; 30(3):227-34. PubMed ID: 22200917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sclerosing cholangitis with autoimmune pancreatitis versus primary sclerosing cholangitis: comparison on endoscopic retrograde cholangiography, MR cholangiography, CT, and MRI.
    Kim JH; Byun JH; Kim SY; Lee SS; Kim HJ; Kim MH; Lee MG
    Acta Radiol; 2013 Jul; 54(6):601-7. PubMed ID: 23528564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolated Main Pancreatic Duct Dilatation: CT Differentiation Between Benign and Malignant Causes.
    Kim SW; Kim SH; Lee DH; Lee SM; Kim YS; Jang JY; Han JK
    AJR Am J Roentgenol; 2017 Nov; 209(5):1046-1055. PubMed ID: 28858540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategy for differentiating autoimmune pancreatitis from pancreatic cancer.
    Kamisawa T; Imai M; Yui Chen P; Tu Y; Egawa N; Tsuruta K; Okamoto A; Suzuki M; Kamata N
    Pancreas; 2008 Oct; 37(3):e62-7. PubMed ID: 18815540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of the focal type of autoimmune pancreatitis in chronic pancreatitis suspected to be pancreatic carcinoma: experience of a single tertiary cancer center.
    Kajiwara M; Gotohda N; Konishi M; Nakagohri T; Takahashi S; Kojima M; Kinoshita T
    Scand J Gastroenterol; 2008 Jan; 43(1):110-6. PubMed ID: 18158696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focal IgG4-related autoimmune pancreatitis with distal choledochal adenocarcinoma: a rare case report.
    Wang H; Yao L; Wang L; Sun X; Huang B
    BMC Gastroenterol; 2021 Nov; 21(1):421. PubMed ID: 34758732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.